Outcomes of bictegravir/emtricitabine/tenofovir alafenamide versus efavirenz-based regimens in central China: a real-world assessment

被引：1
|
作者：
Peng, Yongquan [1 ]
Cao, Xujian [1 ]
Wang, Yating [1 ]
Yu, Weiwei [2 ]
Zeng, Ziwei [2 ]
Wang, Min [2 ]
机构：
[1] Univ South China, Hosp Changsha 1, Grad Collaborat Training Base, Grad Collaborat Training Base, Hengyang 421001, Hunan, Peoples R China
[2] First Hosp Changsha, Inst HIV AIDS, Changsha 410000, Hunan, Peoples R China
来源：
CHINESE MEDICAL JOURNAL | 2023年 / 136卷 / 22期
关键词：
D O I：
10.1097/CM9.0000000000002888
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2738 / 2740
页数：3
相关论文
共 50 条
  • [41] Clinical efficacy, safety, and subjective experience based on ePRO in HIV-infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China
    Kong, Linghong
    Xie, Xiaoxin
    Fu, Yanhua
    Gan, Lin
    Yang, Xiaoyan
    Ma, Shujing
    Long, Hai
    IMMUNITY INFLAMMATION AND DISEASE, 2023, 11 (08)
  • [42] Effectiveness and Safety of Dolutegravir Versus Efavirenz-Based Antiviral Regimen in People Living With HIV-1 in Sichuan Province of China: A Real-World Study
    Tongtong, Yang
    Shenghua, He
    Yin, Wang
    Lin, Cai
    Huanxia, Liu
    Chunrong, Lv
    Ruifeng, Zhou
    Xiaojing, Yang
    Yuan, Yao
    Yuanhong, He
    Ke, Yin
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2022, 91 : S1 - S7
  • [43] Switch from tenofovir disoproxil fumarate (TDF)- to tenofovir alafenamide (TAF)-based regimens in clinical practice: real-world data of the German PROPHET cohort study
    Bickel, M.
    Wyen, C.
    Spinner, C.
    Baumgarten, A.
    Jaeger, H.
    Postel, N.
    Wolf, E.
    Hoffmann, C.
    Esser, S.
    Klauke, S.
    Schewe, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [44] Clinical relevance of potential drug-drug interactions with bictegravir/emtricitabine/tenofovir alafenamide-real-world data from German IQVIA prescription database
    Umland, Tim
    Stellbrink, Hans-Juergen
    Calvo, Marta
    Zahn, Astrid
    INFECTION, 2021, 49 (SUPPL 1) : S22 - S23
  • [45] Real-world effectiveness in treatment-experienced (TE) people with HIV (PWH) switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) with distinct patterns of self-reported adherence
    Boffito, Marta
    Brunetta, Jason
    Levy, Itzchak
    Yang, Chia-Jui
    Portilla, Joaquin
    De Barra, Eoghan
    Vogelmann, Roger
    Endo, Tomoyuki
    Robineau, Olivier
    Sarmati, Loredana
    Thorpe, David
    Marongiu, Andrea
    Cassidy, Tali
    van Welzen, Berend
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 79 - 82
  • [46] Weight gain and metabolic disturbances in people living with HIV who start antiretroviral therapy with, or switch to, bictegravir/emtricitabine/tenofovir alafenamide after 48 weeks of treatment: A real-world prospective study
    Mata Marin, Jose Antonio
    Velasco-Penagos, Juan Carlos
    Mauss, Stefan
    Rodriguez-Evaristo, Mara Soraya
    Perez-Barragan, Edgar
    Villa-Platas, Joaquin
    Barragan-Huerta, Laura
    Gaytan-Martinez, Jesus Enrique
    INTERNATIONAL JOURNAL OF STD & AIDS, 2024, 35 (01) : 33 - 38
  • [47] Patient-reported outcome measures at 12 months in a real-world cohort of people living with HIV receiving bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Europe, Canada, and Israel
    Brunetta, Jason
    Monforte, Antonella
    van Welzen, Berend
    Milinkovic, Ana
    Marongiu, Andrea
    Heinzkill, Marion
    Thorpe, David
    Cornejo, Almudena Torres
    Antela, Antonio
    HIV MEDICINE, 2022, 23 : 76 - 76
  • [48] Effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as switch strategy in virologically-suppressed patients: real world data from a monocentric cohort
    Passerotto, Ra
    Lamanna, F.
    Salvo, Pf
    Iannone, V
    Steiner, Rj
    Carbone, A.
    Farinacci, D.
    D'Angelillo, A.
    Baldin, G.
    Ciccullo, A.
    Di Giambenedetto, S.
    Torti, C.
    Borghetti, A.
    ANTIVIRAL THERAPY, 2024, 29 (06)
  • [49] Comparative Studies on the Efficacy and Safety of Ainuovirine-Based Versus Efavirenz-Based Antiretroviral Therapy in the Management of Persons Living with HIV: A Real-World Study in Guizhou, China
    Guo, Lei
    Fu, Yanhua
    Xie, Xiaoxin
    Yan, Wan
    Long, Hai
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2024, 40 (08) : 482 - 488
  • [50] Real-world clinical outcomes of HIV-1 virologically suppressed adults on bictegravir/emtricitabine/tenofovir alafenamide who switched to long-acting intramuscular cabotegravir plus rilpivirine at 12, 24, and 48-weeks
    Nasser, K.
    Valentin, A. -M.
    Ramgopal, M.
    HIV MEDICINE, 2023, 24 : 161 - 162
12345